Cindy X Cai1, Cindy Skalak1, Robert T Keenan2, Dilraj S Grewal1, Glenn J Jaffe3. 1. Department of Ophthalmology, Duke University Medical Center, Durham, NC, USA. 2. Department of Rheumatology and Immunology, Duke University Medical Center, Durham, NC, USA. 3. Department of Ophthalmology, Duke University Medical Center, Durham, NC, USA. glenn.jaffe@duke.edu.
Abstract
PURPOSE: To determine the time to disease recurrence with long-acting injectable fluocinolone acetonide implant (FAi) for noninfectious intermediate, posterior, and panuveitis. METHODS: This was a retrospective study of patients with at least 12 months of follow-up who had completed a 2-year prospective, investigational new drug study with 0.18-mg FAi. Time to uveitis recurrence or cystoid macular edema (CME) occurrence was recorded. RESULTS: Twelve eyes from 12 participants (mean age 43 years, range 25-64 years) were included. Patients were followed for a mean of 34.2 months (range, 12.0-56.9 months) after completion of the prospective trial. Five eyes (42%) did not have a documented uveitis recurrence or CME occurrence. Five eyes (42%) had a uveitis recurrence with the mean time to recurrence 36.1 months (range, 22.8-61.1 months) after FAi implantation. Two eyes (16%) had CME alone, the mean time to occurrence 36.9 months (range 36.1-42.1 months). On Kaplan-Meier analysis, the estimated probability of remaining recurrence-free 36 months after FAi implantation was 0.67 (95% confidence interval, 0.34-0.86). CONCLUSIONS: Data of study participants after completing a clinical trial suggest that the injectable FAi for noninfectious uveitis can provide control for 3 years on average. These long-term data support the use of FAi to control noninfectious uveitis.
PURPOSE: To determine the time to disease recurrence with long-acting injectable fluocinolone acetonide implant (FAi) for noninfectious intermediate, posterior, and panuveitis. METHODS: This was a retrospective study of patients with at least 12 months of follow-up who had completed a 2-year prospective, investigational new drug study with 0.18-mg FAi. Time to uveitis recurrence or cystoid macular edema (CME) occurrence was recorded. RESULTS: Twelve eyes from 12 participants (mean age 43 years, range 25-64 years) were included. Patients were followed for a mean of 34.2 months (range, 12.0-56.9 months) after completion of the prospective trial. Five eyes (42%) did not have a documented uveitis recurrence or CME occurrence. Five eyes (42%) had a uveitis recurrence with the mean time to recurrence 36.1 months (range, 22.8-61.1 months) after FAi implantation. Two eyes (16%) had CME alone, the mean time to occurrence 36.9 months (range 36.1-42.1 months). On Kaplan-Meier analysis, the estimated probability of remaining recurrence-free 36 months after FAi implantation was 0.67 (95% confidence interval, 0.34-0.86). CONCLUSIONS: Data of study participants after completing a clinical trial suggest that the injectable FAi for noninfectious uveitis can provide control for 3 years on average. These long-term data support the use of FAi to control noninfectious uveitis.
Authors: D A Jabs; J T Rosenbaum; C S Foster; G N Holland; G J Jaffe; J S Louie; R B Nussenblatt; E R Stiehm; H Tessler; R N Van Gelder; S M Whitcup; D Yocum Journal: Am J Ophthalmol Date: 2000-10 Impact factor: 5.258
Authors: Careen Lowder; Rubens Belfort; Sue Lightman; C Stephen Foster; Michael R Robinson; Rhett M Schiffman; Xiao-Yan Li; Harry Cui; Scott M Whitcup Journal: Arch Ophthalmol Date: 2011-01-10
Authors: Glenn J Jaffe; Daniel Martin; David Callanan; P Andrew Pearson; Brian Levy; Timothy Comstock Journal: Ophthalmology Date: 2006-05-09 Impact factor: 12.079
Authors: John H Kempen; Michael M Altaweel; Janet T Holbrook; Douglas A Jabs; Thomas A Louis; Elizabeth A Sugar; Jennifer E Thorne Journal: Ophthalmology Date: 2011-08-15 Impact factor: 12.079
Authors: H Nida Sen; Susan Vitale; Sapna S Gangaputra; Robert B Nussenblatt; Teresa L Liesegang; Grace A Levy-Clarke; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne; C Stephen Foster; Douglas A Jabs; John H Kempen Journal: Ophthalmology Date: 2014-07-11 Impact factor: 12.079
Authors: Glenn J Jaffe; C Stephen Foster; Carlos E Pavesio; Dario A Paggiarino; Gerard E Riedel Journal: Ophthalmology Date: 2018-10-25 Impact factor: 12.079
Authors: Marco Battista; Vincenzo Starace; Maria Vittoria Cicinelli; Luigi Capone; Alessandro Marchese; Giulio Modorati; Francesco Bandello; Elisabetta Miserocchi Journal: Ophthalmol Ther Date: 2021-11-17
Authors: Paulina García-Estrada; Miguel A García-Bon; Edgar J López-Naranjo; Dulce N Basaldúa-Pérez; Arturo Santos; Jose Navarro-Partida Journal: Pharmaceutics Date: 2021-05-12 Impact factor: 6.321